Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives

被引:42
作者
Salam, Kazi Abdus [1 ]
Akimitsu, Nobuyoshi [1 ]
机构
[1] Univ Tokyo, Radioisotope Ctr, Bunkyo Ku, Tokyo 1130032, Japan
关键词
NONSTRUCTURAL PROTEIN; HELICASE ACTIVITY; PEGINTERFERON ALPHA-2A; ACRIDONE DERIVATIVES; RNA REPLICATION; ION-CHANNEL; P7; PROTEIN; RIBAVIRIN; POTENT; IDENTIFICATION;
D O I
10.1155/2013/467869
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Currently, hepatitis C virus (HCV) infection is considered a serious health-care problem all over the world. A good number of direct-acting antivirals (DAAs) against HCV infection are in clinical progress including NS3-4A protease inhibitors, RNA-dependent RNA polymerase inhibitors, and NS5A inhibitors as well as host targeted inhibitors. Two NS3-4A protease inhibitors (telaprevir and boceprevir) have been recently approved for the treatment of hepatitis C in combination with standard of care (pegylated interferon plus ribavirin). The new therapy has significantly improved sustained virologic response (SVR); however, the adverse effects associated with this therapy are still the main concern. In addition to the emergence of viral resistance, other targets must be continually developed. One such underdeveloped target is the helicase portion of the HCV NS3 protein. This review article summarizes our current understanding of HCV treatment, particularly with those of NS3 inhibitors.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Allosteric Inhibitors of the NS3 Protease from the Hepatitis C Virus
    Abian, Olga
    Vega, Sonia
    Sancho, Javier
    Velazquez-Campoy, Adrian
    PLOS ONE, 2013, 8 (07):
  • [2] Novel, sulfonamide linked inhibitors of the hepatitis C virus NS3 protease
    Kirschberg, Thorsten A.
    Squires, Neil H.
    Yang, Huiling
    Corsa, Amoreena C.
    Tian, Yang
    Tirunagari, Neeraj
    Sheng, X. Christopher
    Kim, Choung U.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (03) : 969 - 972
  • [3] Inhibition of Hepatitis C Virus NS3 Helicase by Manoalide
    Salam, Kazi Abdus
    Furuta, Atsushi
    Noda, Naohiro
    Tsuneda, Satoshi
    Sekiguchi, Yuji
    Yamashita, Atsuya
    Moriishi, Kohji
    Nakakoshi, Masamichi
    Tsubuki, Masayoshi
    Tani, Hidenori
    Tanaka, Junichi
    Akimitsu, Nobuyoshi
    JOURNAL OF NATURAL PRODUCTS, 2012, 75 (04): : 650 - 654
  • [4] Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors
    Zeminian, Luciana Bonome
    Padovani, Juliana Lara
    Corvino, Silvia Maria
    Silva, Giovanni Faria
    de Moura Campos Pardini, Maria Ines
    Tommasini Grotto, Rejane Maria
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2013, 108 (01): : 13 - 17
  • [5] Hepatitis C Virus NS3 Protease Is Activated by Low Concentrations of Protease Inhibitors
    Dahl, Goran
    Arenas, Omar Gutierrez
    Danielson, U. Helena
    BIOCHEMISTRY, 2009, 48 (48) : 11592 - 11602
  • [6] RNA binding by the NS3 protease of the hepatitis C virus
    Vaughan, Robert
    Li, Yi
    Fan, Baochang
    Ranjith-Kumar, C. T.
    Kao, C. Cheng
    VIRUS RESEARCH, 2012, 169 (01) : 80 - 90
  • [7] Fuel Specificity of the Hepatitis C Virus NS3 Helicase
    Belon, Craig A.
    Frick, David N.
    JOURNAL OF MOLECULAR BIOLOGY, 2009, 388 (04) : 851 - 864
  • [8] Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel
    Chatel-Chaix, Laurent
    Baril, Martin
    Lamarre, Daniel
    VIRUSES-BASEL, 2010, 2 (08): : 1752 - 1765
  • [9] Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir
    McPhee, Fiona
    Friborg, Jacques
    Levine, Steven
    Chen, Chaoqun
    Falk, Paul
    Yu, Fei
    Hernandez, Dennis
    Lee, Min S.
    Chaniewski, Susan
    Sheaffer, Amy K.
    Pasquinelli, Claudio
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (07) : 3670 - 3681
  • [10] Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors
    Naggie, Susanna
    Patel, Keyur
    McHutchison, John
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (10) : 2063 - 2069